CGEM (Cullinan Therapeutics) Accounts Payable: $3.73 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGEM Cullinan Therapeutics Inc CGEM
22 GF Score
Price $19.01
! 5 Warning Signs
View Full Analysis

What is Cullinan Therapeutics Accounts Payable?

Cullinan Therapeutics CGEM +3.82% 22 Accounts Payable is $3.73 Mil as of Jun. 2026. GuruFocus rates CGEM with a GF Score™ of 22/100. The stock has 5 warning signs investors should review.

Cullinan Therapeutics's Accounts Payable for the quarter that ended in Jun. 2026 was $3.73 Mil.

Cullinan Therapeutics's quarterly Accounts Payable increased from Dec. 2025 ($0.84 Mil) to Mar. 2026 ($2.51 Mil) and increased from Mar. 2026 ($2.51 Mil) to Jun. 2026 ($3.73 Mil).

Cullinan Therapeutics's annual Accounts Payable declined from Dec. 2023 ($2.49 Mil) to Dec. 2024 ($1.68 Mil) and declined from Dec. 2024 ($1.68 Mil) to Dec. 2025 ($0.84 Mil).

Cullinan Therapeutics Accounts Payable Related Terms

Cullinan Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Cullinan Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cullinan Therapeutics Accounts Payable Chart

Cullinan Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 3.17 2.66 2.49 1.68 0.84

Cullinan Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.46 1.72 0.84 2.51 3.73
CGEM
22GF Score
Cullinan Therapeutics Inc CGEM
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cullinan Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $3.73 Mil mean?
Cullinan Therapeutics (CGEM) has a Accounts Payable of $3.73 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cullinan Therapeutics and its competitors.
Is Cullinan Therapeutics' Accounts Payable too high?
Cullinan Therapeutics' current Accounts Payable is $3.73 Mil. Overall, Cullinan Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Cullinan Therapeutics' Accounts Payable compare to VOR and ANRO?
Cullinan Therapeutics' Accounts Payable of $3.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cullinan Therapeutics and its competitors. Cullinan Therapeutics's current Accounts Payable is $3.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cullinan Therapeutics stock overvalued right now?
Cullinan Therapeutics (CGEM) has a current Accounts Payable of $3.73 Mil. The current Accounts Payable is $3.73 Mil. Cullinan Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Cullinan Therapeutics (CGEM), the current Accounts Payable is $3.73 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cullinan Therapeutics Business Description

Address One Main Street, Suite 1350, Cambridge, MA, USA, 02142
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
22GF Score

Get the complete analysis for CGEM

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.01
Price